Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation | Zendy

Takeo Yasu | Zendy; Takaaki Konuma | Zendy; Maki OiwaMonna | Zendy; Seiko Kato | Zendy; Susumu Tanoue | Zendy; Masamichi Isobe | Zendy; Mai Mizusawa | Zendy; Seiichiro Kuroda | Zendy; Satoshi Takahashi | Zendy; Arinobu Tojo | Zendy

Open Access

Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation

Author(s) -

Takeo Yasu,

Takaaki Konuma,

Maki OiwaMonna,

Seiko Kato,

Susumu Tanoue,

Masamichi Isobe,

Mai Mizusawa,

Seiichiro Kuroda,

Satoshi Takahashi,

Arinobu Tojo

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01205-18

Subject(s) - medicine , amphotericin b , transplantation , cord blood , surgery , anesthesia , antifungal , dermatology

Liposomal amphotericin B (L-AMB) is widely used for empirical or preemptive therapy and treatment of invasive fungal infections after cord blood transplantation (CBT). We retrospectively examined the efficacy and safety of low-dose L-AMB in 48 adult patients who underwent CBT between 2006 and 2017 in our institute.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research